All In Biotech

Drug Trial Radar · NCT07738757

SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies

A Phase II Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination With Tagitanlimab (KL-A167) as Second-Line or Later Therapy for MSI-H/dMMR Advanced Gynecological Malignancies: An Open-Label, Single-Arm, Multicenter Exploratory Trial

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Sep 1, 2028

Study completion Dec 30, 2029

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, multicenter, single-arm Phase II study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT/SKB264) in combination with tagitanlimab (KL-A167) as second-line or later therapy in patients with recurrent or metastatic MSI-H/dMMR gynecological malignancies, including endometrial cancer, ovarian cancer, and cervical cancer. The primary objective is to evaluate the objective response rate (ORR) per RECIST v1.1 as assessed by the investigator. Secondary objectives include evaluating overall survival (OS), progression-free survival (PFS) per RECIST v1.1, disease control rate (DCR), duration of response (DoR), and the safety and tolerability of the combination regimen.

Conditions

  • Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies

Interventions

  • Sacituzumab Tirumotecan (Sac-TMT)Drug

    Sac-TMT will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle.

  • TagitanlimabDrug

    KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle. KL-A167 therapy for up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate(ORR)Time frame: up to 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.